Payment overview · 2025
General Payments
$831.84
42 reported records · 13 companies
Healthcare provider profile · identity verified
David Speizman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1952356685
Verified facts
What the public records show
CMS Open Payments records show David Speizman, DO received $831.84 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $178.03 | 21.4% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $149.05 | 17.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.03 | 13.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.74 | 9.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.20 | 8.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.69 | 7.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.12 | 6.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.42 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.81 | 2.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.87 | 2.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.51 | 2.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.80 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.57 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $831.84 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $98.74 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.04 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.04 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $79.29 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.29 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $72.04 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.14 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.45 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1358 | 416 |
| Amlodipine Besylate | Amlodipine Besylate | 659 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 190 |
| Losartan Potassium | Losartan Potassium | 608 | 192 |
| Alprazolam | Alprazolam | 488 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 441 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 141 |
| Lisinopril | Lisinopril | 399 | 122 |
| Metformin Hcl | Metformin Hcl | 380 | 118 |
| Omeprazole | Omeprazole | 359 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 78 |
| Methylprednisolone | Methylprednisolone | 226 | 176 |
| Gabapentin | Gabapentin | 210 | 73 |
| Simvastatin | Simvastatin | 210 | 66 |
| Eliquis | Apixaban | 206 | 56 |
| Atenolol | Atenolol | 181 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 60 |
| Trazodone Hcl | Trazodone Hcl | 176 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 51 |
| Temazepam | Temazepam | 145 | 47 |
| Tramadol Hcl | Tramadol Hcl | 142 | 57 |
| Allopurinol | Allopurinol | 141 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 42 |
| Famotidine | Famotidine | 137 | 52 |
| Carvedilol | Carvedilol | 128 | 40 |
| Ezetimibe | Ezetimibe | 128 | 44 |
| Furosemide | Furosemide | 126 | 46 |
| Spironolactone | Spironolactone | 110 | 45 |
| Diazepam | Diazepam | 109 | 23 |
| Valsartan | Valsartan | 109 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 47 |
| Sertraline Hcl | Sertraline Hcl | 107 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 38 |
| Finasteride | Finasteride | 105 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 84 | 24 |
| Montelukast Sodium | Montelukast Sodium | 82 | 30 |
| Glimepiride | Glimepiride | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 33 |
| Azithromycin | Azithromycin | 75 | 70 |
| Mirtazapine | Mirtazapine | 75 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 26 |
| Celecoxib | Celecoxib | 72 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 20 |
| Potassium Chloride | Potassium Chloride | 67 | 26 |
| Xarelto | Rivaroxaban | 65 | 18 |
| Donepezil Hcl | Donepezil Hcl | 64 | 19 |
| Farxiga | Dapagliflozin Propanediol | 64 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 18 |
| Lorazepam | Lorazepam | 63 | 27 |
| Labetalol Hcl | Labetalol Hcl | 62 | 13 |
| Jardiance | Empagliflozin | 61 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 48 |
| Ozempic | Semaglutide | 55 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 17 |
| Metformin Hcl Er | Metformin Hcl | 54 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 28 |
| Alendronate Sodium | Alendronate Sodium | 50 | 20 |
| Clonazepam | Clonazepam | 45 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 26 |
| Lovastatin | Lovastatin | 45 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 11 |
| Fenofibrate | Fenofibrate | 43 | 14 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | 15 |
| Benazepril Hcl | Benazepril Hcl | 40 | 13 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | 12 |
| Meloxicam | Meloxicam | 34 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Linzess | Linaclotide | 31 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Prednisone | Prednisone | 29 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | 13 |
| Torsemide | Torsemide | 28 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 20 |
| Azelastine Hcl | Azelastine Hcl | 23 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 15 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 11 |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Primidone | Primidone | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 11 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $831.84 · 42 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Leqembi, MOUNJARO, ONPATTRO, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error